Skip to main content
. 2015 Mar 26;6(14):11794–11805. doi: 10.18632/oncotarget.3649

Table 1. Relationship between ERp19 expression level and clinicopathological variables in 90 GC patients.

Clinicopathological variable No. of patients ERp19 staining P value
Weak Strong
Normal tissue 90 56 34 0.007*
Gastric carcinoma 90 38 52
Age (years) 0.423
  <60 29 14 15
  ≽60 61 24 37
Gender 0.728
  Male 67 29 38
  Female 23 9 14
Tumor size (cm) 0.041*
  ≼5 34 19 15
  >5 56 19 37
Histological grade 0.584
  Well, Moderately 24 9 15
  Poorly, undifferentiated 66 29 37
Lauren's classification 0.108
  Intestinal-type 56 20 36
  Diffuse-type 34 18 16
Lymph node involvement 0.034*
  Absence 25 15 10
  Presence 65 23 42
TNM stage 0.433
  I+II 36 17 19
  III+IV 54 21 33

Immunohistochemistry (IHC) scores were calculated by multiplying the percentage of positive cells (0 is <5% positive cells, 1 is 5%-25% positive cells, 2 is 25%-50% positive cells, 3 is 50%-75% positive cells and 4 is >75% positive cells) by stain intensity (0 is no staining, 1 is weak staining, 2 is moderate staining and 3 is strong staining) in five different high power fields for each section. The IHC score of 0-3 was defined as weak expression and 4-12 as strong expression.